Comprehensive characterization of reference standard lots of HIV-1 subtype C Gp120 proteins for clinical trials in southern African regions

Vaccines

Volumn 4, Issue 2, 2016, Pages

  Wang, Zihao ^a   Lorin, Clarisse ^b   Koutsoukos, Marguerite ^b   Franco, David ^b   Bayat, Babak ^b   Zhang, Ying ^a   Carfi, Andrea ^a   Barnett, Susan W ^a   Porter, Frederick ^a  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (Belgium)

Author keywords

Antigens; Characterization; Clinical trial; Gp120; HIV 1; Immunogenicity; Vaccine

Indexed keywords

ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

AFRICA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHO CELL LINE; CIRCULAR DICHROISM; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNOGENICITY; ISOELECTRIC FOCUSING; MELTING POINT; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PEPTIDE MAPPING; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; VACCINATION;

EID: 85016876665     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines4020017     Document Type: Article

References (20)

1. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209–2220. [CrossRef] [PubMed]
2. Robb, M.L.; Rerks-Ngarm, S.; Nitayaphan, S.; Pitisuttithum, P.; Kaewkungwal, J.; Kunasol, P.; Khamboonruang, C.; Thongcharoen, P.; Morgan, P.; Benenson, M.; et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect. Dis. 2012, 12, 531–537. [CrossRef]
3. Haynes, B.F.; Gilbert, P.B.; McElrath, M.J.; Zolla-Pazner, S.; Tomaras, G.D.; Alam, S.M.; Evans, D.T.; Montefiori, D.C.; Karnasuta, C.; Sutthent, R.; et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366, 1275–1286. [CrossRef] [PubMed]
4. Ping, L.H.; Joseph, S.B.; Anderson, J.A.; Abrahams, M.R.; Salazar-Gonzalez, J.F.; Kincer, L.P.; Treurnicht, F.K.; Arney, L.; Ojeda, S.; Zhang, M.; et al. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J. Virol. 2013, 87, 7218–7233. [CrossRef] [PubMed]
5. Chun, T.; Murray, D.; Justement, J.S.; Blazkova, J.; Hallahan, C.W.; Fankuchen, O.; Gittens, K.; Benko, E.; Kovacs, C.; Moir, S.; et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc. Natl. Acad. Sci. USA 2014, 111, 13151–13156. [CrossRef] [PubMed]
6. Sanders, R.W.; Venturi, M.; Schiffner, L.; Kalyanaraman, R.; Katinger, H.; Lloyd, K.O.; Kwong, P.D.; Moore, J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76, 7293–7305. [CrossRef] [PubMed]
7. Pejchal, R.; Doores, K.J.; Walker, L.M.; Khayat, R.; Huang, P.S.; Wang, S.K.; Stanfield, R.L.; Julien, J.P.; Ramos, A.; Crispin, M.; et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334, 1097–1103. [CrossRef] [PubMed]
8. Pancera, M.; Shahzad-ul-Hussan, S.; Doria-Rose, N.A.; McLellan, J.S.; Bailer, R.T.; Dai, K.; Loesgen, S.; Louder, M.K.; Staupe, R.P.; Yang, Y.; et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 2013, 20, 804–814. [CrossRef] [PubMed]
9. Zhou, T.; Xu, L.; Dey, B.; Hessell, A.J.; Van Ryk, D.; Xiang, S.H.; Yang, X.; Zhang, M.Y.; Zwick, M.B.; Arthos, J.; et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445, 732–737. [CrossRef] [PubMed]
10. Zambonelli, C.; Dey, A.K.; Hilt, S.; Stephenson, S.; Go, E.P.; Clark, D.F.; Wininger, M.; Labranche, C.; Montefiori, D.; Liao, H.; et al. GSK Vaccines. Unpublished data 2016.
11. Totrov, M. Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant. PLoS ONE 2014, 9, e94002. [CrossRef] [PubMed]
12. Yu, B.; Fonseca, D.; O’Rourke, S.; Berman, P. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. J. Virol. 2010, 84, 1513–1526. [CrossRef] [PubMed]
13. Robert, F.; Bierau, H.; Rossi, M.; Agugiaro, D.; Soranzo, T.; Broly, H.; Mitchell-Logean, C. Degradation of an Fc-fusion recombinant protein by host cell proteases: Identification of a CHO cathepsin D protease. Biotechnol. Bioeng. 2009, 104, 1132–1141. [CrossRef] [PubMed]
14. Bernstein, H.B.; Tucker, S.P.; Hunter, E.; Schutzbach, J.S.; Compans, R.W. Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J. Virol. 1994, 68, 463–468. [PubMed]
15. Yang, W.; Shah, P.; Eshghi, S.T.; Yang, S.; Sun, S.; Ao, M.; Rubin, A.; Jackson, J.B.; Zhang, H. Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy. Anal. Chem. 2014, 86, 6959–6967. [CrossRef] [PubMed]
16. Go, E.P.; Liao, H.; Alam, S.M.; Hua, D.; Haynes, B.F.; Desaire, H. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 2013, 12, 1223–1234. [CrossRef] [PubMed]
17. Bonomelli, C.; Doores, K.J.; Dunlop, D.C.; Thaney, V.; Dwek, R.A.; Burton, D.R.; Crispin, M.; Scanlan, C.N. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 2011, 6, e23521. [CrossRef] [PubMed]
18. Go, E.P.; Zhang, Y.; Menon, S.; Desaire, H. Analysis of the disulfide bond arrangement of the HIV envelope protein CON-S gp140 DCFI shows variability in the V1 and V2 regions. J. Proteome Res. 2011, 10, 578–591. [CrossRef] [PubMed]
19. Finzi, A.; Pacheco, B.; Zeng, X.; Kwon, Y.D.; Kwong, P.D.; Sodroski, J. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J. Virol. Methods 2010, 168, 155–161. [CrossRef] [PubMed]
20. Coutu, M.; Finzi, A. HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. J. Virol. Methods 2015. [CrossRef] [PubMed]